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Introduction  and  aims:  There  is  no  systematized  information  for  determining/monitoring  the
burden of  inflammatory  bowel  disease  in  Mexico.  The  aim  of  the  present  study  was  to  estimate
the annual  burden  of  inflammatory  bowel  disease  on  the  Mexican  National  Healthcare  System,
by number  of  patients  seen,  hospitalizations,  and  specific  deaths,  stratified  into  age  groups.
Materials and  methods:  Utilizing  specific  databases  of  the  Mexican  National  Healthcare  System
registries  coded  as  ICD-10:  K50  and  K51,  we  retrieved  and  analyzed  the  data  corresponding  to
the patients  seen  and  hospitalized  in  2015,  stratified  by  age  group,  as  well  as  the  specific  deaths.
Treatment trends  among  physicians  were  also  examined.
Results:  In  2015,  5009  women  (8.1)  and  4944  men  (8.4)  with  Crohn’s  disease  received  medical
attention  (prevalence  of  cases  seen)  and  35.1%  of  those  patients  were  ≥50  years  of  age.  In
that same  period,  17,177  women  (27.7)  and  15,883  men  (26.9)  with  ulcerative  colitis  were
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seen  and  31.6%  of  those  patients  were  ≥50  years  of  age.  The  hospitalized  cases  (prevalence  of
hospitalized  cases)  were  1097  patients  (0.91)  with  Crohn’s  disease  and  43.7%  of  those  patients
were ≥50  years  of  age;  and  5345  patients  (4.42)  with  ulcerative  colitis  and  47.6%  of  those
patients were  ≥50  years  of  age.  Deaths  (specific  mortality  rate)  were:  32  women  (0.52)  and  36
men (0.50)  due  to  Crohn’s  disease,  and  267  women  (4.31)  and  186  men  (3.15)  due  to  ulcerative
colitis.
Conclusions:  Inflammatory  bowel  disease  is  a  burden  on  the  health  of  Mexican  adults  and  the
Mexican National  Healthcare  System,  and  it  is  expected  to  increase  over  the  next  15  years.
© 2020  Asociación  Mexicana  de  Gastroenteroloǵıa.  Published  by  Masson  Doyma  México  S.A.  This











Base  de  datos  de
registros
Epidemiología,  carga  de  la  enfermedad  y  tendencias  de  tratamiento  de  la
enfermedad  inflamatoria  intestinal  en  México
Resumen
Introducción  y  objetivos:  En  México  no  existe  información  sistematizada  para  determi-
nar/monitorizar  la  carga  de  la  enfermedad  inflamatoria  intestinal  (EII).  El  objetivo  del  estudio
fue estimar  la  carga  anual  de  la  EII  en  el  Sistema  Nacional  de  Salud  por  número  de  pacientes
atendidos,  hospitalizaciones  y  muertes  y  por  grupos  de  edad.
Material  y  métodos: Utilizando  registros  específicos  de  bases  de  datos  del  Sistema  Nacional  de
Salud codificados  por  CIE-10:  K50  y  K51,  obtuvimos  y  analizamos  datos  correspondientes  a  los
pacientes atendidos  y  hospitalizados  por  grupo  etario,  así  como  muertes  específicas  durante  el
año 2015.  Asimismo,  se  exploró  la  tendencia  de  tratamiento  entre  médicos.
Resultados:  En  2015,  el  número  total  de  casos  atendidos  (prevalencia  de  casos  atendidos)  fue:
enfermedad  de  Crohn  en  mujeres  5,009  (8.1),  en  hombres  4,944  (8.4).  Los  pacientes  ≥50  años
representaron  el  35.1%  del  total;  colitis  ulcerosa  crónica  idiopática  en  mujeres  17,177  (27.7),  en
hombres  15,883  (26.9).  Los  ≥50  años  representaron  el  31.6%  del  total.  Los  casos  hospitalizados
fueron (prevalencia  de  casos  hospitalizados):  enfermedad  de  Crohn  1,097  (0.91).  Los  pacientes
≥50 años  representaron  el  43.7%  del  total;  colitis  ulcerosa  crónica  idiopática  5,345  (4.42).  Los
enfermos ≥50  años  representaron  el  47.6%  del  total.  Las  defunciones  fueron  (tasa  de  muertes
específicas):  en  enfermedad  de  Crohn:  mujeres  32  (0.52),  hombres  36  (0.50);  colitis  ulcerosa
crónica idiopática  en  mujeres  267  (4.31),  en  hombres  186  (3.15).
Conclusiones:  La  EII  representa  una  carga  para  la  salud  de  los  adultos  mexicanos  y  el  Sistema
de Salud,  y  se  espera  que  aumente  en  los  próximos  15  años.
© 2020  Asociación  Mexicana  de  Gastroenteroloǵıa.  Publicado  por  Masson  Doyma  México  S.A.















growth  in  the  incidence  of  IBD.5 For  example,  the  incidenceIntroduction and aims
Ulcerative  colitis  (UC)  and  Crohn’s  Disease  (CD)  are  the  two
main  forms  of  inflammatory  bowel  disease  (IBD).  Despite
some  common  characteristics,  they  can  be  distinguished
from  one  another  by  differences  in  genetic  predisposition,
risk  factors,  and  clinical,  endoscopic,  and  histologic  findings.
Although  the  exact  cause  of  IBD  is  unknown,  genetically  sus-
ceptible  individuals  appear  to  have  a  dysregulated  immune
response  in  the  mucosa  and  gut  microbiota,  resulting  in
bowel  inflammation.1 Another  distinctive  feature  of  IBD  is  its
epidemiologic  profile,  which  varies  geographically,  imposing
a  serious  burden  upon  the  health  systems  of  both  developing
and  industrialized  countries.Since  the  beginning  of  the  21st  century,  IBD  has  become
a  worldwide  public  health  problem,2,3 given  the  high  num-




ortality,  and  an  increase  in  direct  medical  cost  with  the
dvent  of  biologic  therapy.4 In  North  America  and  Europe
lone,  around  1.5  million  and  2  million  people,  respectively,
uffer  from  the  disease.3 Although  the  incidence  of  CD  and
C  is  stabilizing  in  Western  countries,  the  burden  of  dis-
ase  remains  on  the  rise  because  its  prevalence  continues
o  grow,  consuming  healthcare  resources.2,3 At  the  same
ime,  the  incidence  of  IBD  may  be  increasing  rapidly  in  South
merica,  Eastern  Europe,  Asia,  and  Africa,3 compared  with
estern  societies.  Indeed,  the  incidence  of  IBD  is  increas-
ng  in  the  developing  world  and  in  regions  in  the  process
f  cultural  westernization.3 Such  is  the  case  of  Latin  Amer-
ca,  where  countries  like  Brazil  have  experienced  an  annualf  CD  increased  by  42.2%  in  Spain,  whereas  it  increased
y  140.6%  in  Latin  America.  Similarly,  the  incidence  of  UC












































































































merica,  highlighting  contrasting  trends  in  two  populations
f  Hispanic  origin.6 However,  the  lack  of  data  in  countries
ike  Mexico,  creates  a  challenge  for  understanding  the  bur-
en  of  IBD  in  Latin  America.
Previous  studies  on  IBD  in  Mexico  mirror  the  epi-
emiologic  profile  of  the  region  but  have  methodological
hortcomings.  Yamamoto-Furusho7 found  that  the  aver-
ge  annual  number  of  new  cases  increased  from  28.8
1987--1996)  to  76.1  (1997--2006),  signifying  a  2.6-fold
ncrease  in  the  average  annual  incidence,  comparing  both
eriods  (p  <  0.00008).  In  addition,  Bosques-Padilla  et  al.8
ound  that  in  5  years  (2004--2008),  the  adjusted  annual
ate  of  hospitalizations  due  to  UC  in  the  internal  medicine
ervice  at  a  tertiary  care  hospital  center  in  Northwest  Mex-
co,  was  2.3,  2.6,  3.0,  3.6,  and  4.1/1000  hospitalizations,
espectively,  representing  a  1.7-fold  increase  and  raising  the
nnual  average  of  new  cases  from  17  to  29  (p  <  0.05).  Unfor-
unately,  those  studies  were  conducted  at  single  centers  and
o  may  not  fully  represent  the  epidemiology  of  the  country.
oreover,  the  detailed  epidemiologic  information  required
o  assess  IBD  on  a  greater  scale  could  not  be  included  in
hose  studies  due  to  their  design.
Given  the  current  increase  in  incidence,  prevalence,
ortality,  and  healthcare  resources  needed  for  the  mana-
ement  of  IBD  worldwide,  and  the  incremental  behavior  of
hose  indicators,  particularly  in  Latin  America,  along  with
he  lack  of  updated  national  information  in  Mexico  that  can
e  systematized,  monitored,  and  thus  compared  and  man-
ged,  we  decided  to  locally  investigate  different  aspects  of
he  disease.
Based  on  the  abovementioned,  our  aim  was  to  estimate
he  burden  of  disease  of  IBD  in  Mexico  and  examine  the
ehavior  of  disease  activity,  as  well  as  its  specific  treatment.
aterials and methods
or  the  construction  of  the  epidemiologic  and  patient  care
ata  (inpatients  and  outpatients),  a  retrospective  analy-
is  of  local  data  sources  from  the  national  health  system
as  conducted  to  estimate  the  burden  of  disease  of  IBD
n  Mexico.  Data  were  stratified  by  age  groups,  to  reveal
he  prevalence  rates  of  patient  care  (inpatients  and  out-
atients),  as  well  as  reported  deaths  from  that  cause,  to
ecognize  the  2015  annual  burden  of  IBD  in  Mexico.  In  addi-
ion,  to  estimate  the  distribution  of  IBD  patients  by  severity
nd  clinical  activity,  as  well  as  by  type  of  treatment,  physi-
ians  experienced  in  the  treatment  of  patients  with  IBD  were
nterviewed.
The  data  sources  consulted  were  different  health  and
nformation  agencies  within  the  Mexican  healthcare  sys-
em,  obtaining  the  specific  relevant  information,  either
nline  or  by  special  written  request  (institutional  year-
ooks  and  institutional  statistics  reports,  statistical  reports
f  morbidity  and  hospitalization  from  the  national  system
f  health  information,  health  statistics  from  private  insti-
utions,  cause-specific  mortality  statistics,  etc.).9--14 The
opulation  pyramid  of  Mexico,  specific  and  updated  to  2015
by  sex  and  age  groups),  was  obtained  from  official  Mexican
overnment  sources.15,16
Because  neither  formal  epidemiologic  studies,  nor
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s  followed  clinically  for  a  certain  period,  are  available  sys-
ematically  for  the  diagnosis  of  IBD  in  Mexico,  it  was  decided
o  estimate  a  surrogate  prevalence  of  the  pathologies  (CD
nd  UC)  with  a  proxy  variable.  The  information  taken  as
he  proxy  variable  was  the  total  number  of  patients  with
D  (ICD-10:  K50)  or  UC  (ICD-10:  K51)  that  received  medi-
al  attention  within  the  national  healthcare  system  for  a
omplete  year  (2015),  based  on  the  fact  that  it  could  be
tandardized,  and  thus  compared  with  different  healthcare
ystems  (countries),  as  well  as  at  different  periods  on  the
imeline.  Thus,  the  prevalence  of  cases  of  CD  and  UC  seen
ver  a one-year  period  was  estimated.
To  obtain  the  total  number  of  cases  of  CD  and  UC  (ICD-
0  code  K50;  K51)  registered  as  having  received  medical
ttention  for  one  year  (inpatients  and  outpatients)  within
he  Mexican  health  system,  specific  databases  and  queries
f  reported  CD  and  UC  cases  were  employed.  We  searched
or  the  cases  reported  in  2015  by  the  ICD-10  codes:  K50.0,
50.1,  K50.8,  and  K50.9  for  CD;  and  K51.0,  K51.1,  K15.7,
51.3,  K51.4,  K51.5,  K51.8,  and  K57.9  for  UC,  by  sex  and
ge  group.  The  data  were  collected  by  age  group,  as  follows:
20,  20--29,  30--39,  40--49,  50--59,  60--69,  and  ≥70  years.
he  number  of  cases  in  each  age  group  were  then  divided
nto  the  population  of  each  age  group/100,000  inhabitants,
btaining  the  prevalence  rate  of  patients  that  received
edical  attention  within  the  Mexican  healthcare  system  for
00,000  person-years.
The  total  number  of  specific  deaths  registered  (ICD-
0:  K50.0,  K50.1,  K50.8,  and  K50.9  for  CD;  and  K51.0,
51.1,  K15.7,  K51.3,  K51.4,  K51.5,  K51.8,  and  K57.9  for
C)  was  obtained  from  the  corresponding  official  Mexican
ource.9 Said  number  (total  deaths  due  to  CD  or  UC  as  the
rimary  cause,  respectively)  was  divided  into  the  popula-
ion/100,000  inhabitants,  for  each  age  group,  estimating
oth  the  total  and  the  specific  mortality  rate  by  age  group
or  Mexico  (2015).
Given  that  IBD  is  not  a  disease  that  requires  mandatory
eporting  in  Mexico,  it  was  not  possible  to  gather  information
n  that  manner  to  estimate  the  incidence  of  ICD-10:  K50;
51.  In  addition,  the  ICD-10:  K50;  K51  coded  registries  from
he  healthcare  system  databases  of  the  patients  seen  do
ot  distinguish  between  a  new  or  subsequent  patient,  and
o  it  was  not  possible  to  construct  a  rate  of  incidence  of  the
ondition.
tatistical  analysis
or  the  distribution  of  patients  by  clinical  status  and  type  of
reatment,  a  panel  of  specialists  with  extensive  experience
n  IBD  treatment  was  created.  A  specific  instrument  for  data
ollection  was  designed,  which  was  applied  to  the  panelists
ccording  to  the  Delphi  methodology.17 The  questions  were
repared  on  the  basis  of  a  focused  review  of  the  national  and
nternational  medical  literature  available  up  to  2017.18--24
 basic  statistical  analysis  was  carried  out  on  the  resulting
nformation,  estimating  central  tendency  measures  (mean)
nd  dispersion  (standard  deviation  and  95%  confidence
ntervals).  The  panel  included  physicians  from  the  private
nd  public  sectors  within  the  national  health  system.  The
ample  size  was  not  statistically  representative,  given  that
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Table  1  Inflammatory  bowel  disease  in  Mexico  in  2015:  patients  seen,  patients  hospitalized,  and  cause-specific  deaths.
Crohn’s  disease  Ulcerative  colitis
Female  Male  Female  Male
Patients  seen  5009  4944  17,177  15,883
Patients hospitalized  332  298  467  124
Hospitalizations  1097  5345
Death rates  32  36  267  186
Patients (×100,000  inhabitants)a 8.1  8.4  27.7  26.9
Patients hospitalized  (×100,000  inhabitants)b 0.54 0.50 1.76  1.80
Hospitalizations  (patient/year)c 1.74 2.48
Mortality  (×100,000  inhabitants-year)d 0.52 0.61 4.31 3.15
a Patients seen × 100,000 inhabitants-year.
b Patients hospitalized × 100,000 inhabitants-year.
c Hospitalization average × hospitalized patient-year.
d Specific mortality × 100,000 inhabitants-year.
Table  2  Inflammatory  bowel  disease  in  Mexico  in  2015:  patients  seen  and  hospitalized,  by  age  group.
Disease  Age  groups
<20  years  20--29  years  30--39  years  40--49  years  50--59  years  60--69  years  ≥70  years
Crohn’s  disease  12.5%  17.8%  14.6%  11.4%  8.1%  23.2%  12.4%
Patients hospitalized  79  112  92  72  51  146  78
% 9.3%  28.8%  12.1%  14.7%  10.1%  18.7%  6.2%
Patients seen  921  2862  1207  1468  1007  1866  622
Ulcerative colitis  10.5%  18.5%  13.0%  10.4%  15.6%  22.4%  9.6%
Patients hospitalized  227  399  280  223  336  483  206
% 14.5%  22.5%  17.3%  14.0%  11.6%  10.4%  9.6%




















the  purpose  of  the  exercise  was  to  obtain  information  of  a
qualitative  nature  to  demonstrate  a  trend.
Finally,  the  total  number  of  CD  and  UC  patients  that
received  medical  attention  (ICD-10  coded  registries)  in  2015
was  obtained  by  age  group  and  sex,  and  distributed  by
clinical  status  and  type  of  treatment,  according  to  the  infor-
mation  from  the  Delphi  panel.
Ethical  considerations
The  sources  of  information  of  the  present  study  were:
administrative  healthcare  databases  (public  and  open
access),  corresponding  to  Irreversibly  Dissociated
Anonymized  Records  (IDAR),  which  do  not  allow  access  to
personal  data  that  may  be  associated  with  an  identifiable
person;  a  bibliographic  review;  and  a  Delphi  panel  of
physicians.  Therefore,  it  was  exempt  from  the  need  for
review  by  an  ethics  committee.Results
Within  the  year  2015,  9953  cases  with  CD  and  33,060





ttention.  Accordingly,  the  prevalence  of  cases  seen  (cases
een/100,000  inhabitants)  was  the  following:  CD,  8.1  for
omen  and  8.4  for  men;  UC  27.7  for  women  and  26.9  for  men
Table  1).  There  were  1097  hospitalized  cases  with  CD  and
345  with  UC  in  2015,  with  a  prevalence  of  hospitalization
hospitalized  cases/100,000  inhabitants)  of  0.54  for  women
nd  0.50  for  men  with  CD  and  1.76  for  women  and  1.80
or  men  with  UC.  The  average  hospitalization  rate  per  inpa-
ient  case  (number  of  hospitalizations  in  one  year/number
f  yearly  inpatients)  was  1.74  (CD)  and  2.48  (UC)  (Table  1).
n  the  entire  year,  68  deaths  from  CD  were  reported,  with  a
ate  of  0.52  for  women  and  0.61  for  men  (mortality  by  ICD-
0:  K50/100,000  persons-year).  There  were  453  deaths  from
C,  with  rates  of  4.31  and  3.15  for  women  and  men,  respec-
ively  (mortality  by  ICD-10:  K51/100,000  persons-year).  The
nformation  refers  to  primary  causes  of  death  in  the  register
Table  1).
By age  group,  it  was  apparent  both  in  UC  and  CD  that
he  peak  was  in  the  group  of  20--40  years  of  age  (39.9  and
0.9%,  respectively).  For  hospitalized  patients,  the  curves
howed  two  concentration  peaks:  in  CD  in  the  groups  ≥60
ears  of  age  (35.6%)  and  20--40  years  of  age  (32.4%),  and  in
C  in  the  groups  ≥60  years  of  age  (32.0%)  and  20--40  years
f  age  (31.5%)  (Table  2).
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Table  3  Inflammatory  bowel  disease  in  Mexico  in  2015:  patients  by  disease  severity  or  activity.
Crohn’s  disease
Mild  Moderate  Severe
By  degree  of  severity  (CDAI)a 4938  3943  1072
49.6% 39.6%  10.8%
% Remission  Moderately  active  Markedly  active
By  simplified  index  of  activity  (HBI)b 3369  6345  239
Ulcerative  Colitis
Mild  Moderate  Severe
By  degree  of  severity  (Truelove)c 17,204  10,249  5607
% 52.0%  31.0%  17.0%
0 1  2  3
By degree  of  severity  (Mayo)d 1504  8642  12,771  10,143
% 4.6%  26.1%  38.6%  30.7%
a Crohn’s disease activity index.
b Harvey Bradshaw Index.































Table  4  Inflammatory  bowel  disease  in  Mexico  in  2015:
Crohn’s  disease,  treatment  by  clinical  status,  and  healthcare
setting.
Public  Private
First-line  treatment  (CDAI  mild)
Induction  therapy
Mesalazine  46.5%  47.9%
Sulfasalazine  5.4%  4.4%
Budesonide  26.5%  27.2%
Prednisone  21.6%  20.5%
Second-line  treatment  (CDAI  moderate-to-severe)
Remission  therapy
Azathioprine  30.0%  29.8%
Prednisone  23.1%  23.6%
Adalimumab  20.8%  20.9%
Azathioprine  +  infliximab  6.7%  8.3%
Azathioprine  +  adalimumab  5.2%  5.3%
Infliximab  4.1%  3.0%
6 Mercaptopurine  3.7%  3.0%
Methotrexate  2.5%  3.0%
6 Mercaptopurine  +  infliximab  2.2%  2.0%
6 Mercaptopurine  +  adalimumab  1.8%  1.1%
Maintenance  therapy
Azathioprine  47.3%  48.9%
Adalimumab  36.4%  35.6%
Methotrexate  6.0%  6.2%
Infliximab  5.7%  5.1%
6 Mercaptopurine 4.6%  4.2%
Adjuvant  treatment
Adalimumab  42.2%  41.5%The  distribution  of  patients  by  severity  or  activity
n  accordance  with  the  most  widely  used  measurement
cales18--24 was:  in  the  cases  with  CD,  50.4%  of  the  patients
ere  classified  as  moderate-to-severe  (Crohn’s  disease
ctivity  index  [CDAI]),  and  66.2%  as  moderately  active-
arkedly  active  (Harvey  Bradshaw  index  [HBI]).  In  the  cases
ith  UC,  48.0%  of  the  patients  were  ranked  as  moderate-
o-severe  (Truelove  and  Witts  criteria),  and  69.3%  in  grades
--3  of  the  Mayo  scale  (Table  3).
The  site  of  patient  care  and  hospitalization  had  the  fol-
owing  distribution:  for  CD,  of  the  9953  cases  seen,  2128
21.4%)  corresponded  to  the  private  sector  and  7825  (78.6%)
o  the  public  sector,  and  of  the  630  hospitalized  cases,  117
18.6%)  were  from  the  private  sector,  and  513  (81.4%)  from
he  public  sector;  for  UC,  of  the  33,060  cases  seen,  6142
18.6%)  were  from  the  private  sector  and  29,918  (81.4%)
rom  the  public  sector,  and  of  the  2154  hospitalized  cases,
50  (20.9%)  were  from  the  private  sector,  and  1704  (79.1%)
rom  the  public  sector.9--14
In  Tables  4  and  5,  the  distribution  of  the  different
reatments  is  presented  according  to  disease  severity  and
ctivity,  and  to  the  healthcare  setting.  Anti-TNF  therapy
as  used  in  an  average  of  28%  of  the  cases  of  CD  (in  both
he  public  and  private  sectors),  whereas  it  was  used  in  19%
f  the  cases  of  UC  (in  both  the  public  and  private  sec-
ors).
Table  6  shows  the  rates  of  treatment-refractory  patients
n  relation  to  the  different  lines  of  treatment  by  healthcare
etting.
iscussionhe  present  study  investigated  and  analyzed  indicators  that
nable  assessment  of  the  burden  of  IBD  in  Mexico,  using  the
ocal  information  available.  The  study  confirms  the  great
Azathioprine  32.5%  33.0%
Infliximab  17.6%  19.9%
Mercaptopurine  7.8%  5.7%
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Table  5  Inflammatory  bowel  disease  in  Mexico  in  2015:  ulcerative  colitis  (UC),  treatment  by  clinical  status,  and  healthcare
setting.
Public  Private
Remission  treatment  (mild-to-moderate  UC)
Mesalazine  70.4%  69.9%
Infliximab  17.0%  17.2%
Sulfasalazine  8.6%  7.2%
Adalimumab  4.0%  5.7%
Remission  treatment  (corticosteroid  resistant-corticosteroid  dependent  mild-to-moderate  UC)
Azathioprine  70.5%  68.9%
Infliximab  14.9%  14.5%
6 Mercaptopurine 7.5%  6.8%
Adalimumab  4.9%  5.5%
Cyclosporine  2.3%  4.5%
Remission  treatment  (severe  UC)
Systemic  corticosteroid  76.4%  75.5%
Infliximab  12.2%  11.9%
Cyclosporine  8.0%  7.6%
Elective colectomy  3.4%  4.9%
Remission  treatment  (corticosteroid  resistant-corticosteroid  dependent  severe  UC)
Infliximab  77.9%  76.0%
Cyclosporine  16.1%  15.5%
Elective colectomy 6.0%  8.5%
Maintenance  treatment  (mild-to-moderate  UC)
Oral mesalazine  80.3%  80.7%
Oral +  topical  mesalazine  19.7%  19.3%
Maintenance  treatment  (corticosteroid  resistant-corticosteroid  dependent  mild-to-moderate  UC)
Azathioprine  75.5%  76.8%
Infliximab  17.8%  16.2%
Mercaptopurine  3.5%  3.9%
Elective colectomy 3.2%  3.1%
Maintenance  treatment  (severe  UC)
Azathioprine  36.3%  35.7%
Azathioprine  +  cyclosporine  (3  months)  +  corticosteroids  34.2%  33.9%
Infliximab  +  azathioprine  19.7%  18.9%
Mercaptopurine  6.9%  7.0%













variability  of  prevalence  rates  reported  for  IBD  (for  every
100,000  inhabitants),  laying  the  groundwork  for  its  economic
evaluation  in  Mexico,  as  well  as  highlighting  the  increasing
mortality  rates  due  to  IBD  in  Mexico.  The  average  use  of
biologic  therapy  was  higher  in  Mexico,  compared  with  other
populations.  We  discuss  our  findings  with  respect  to  previous
evidence.
The  results  document  a  prevalence  of  CD  ranging  from
8.1  to  8.4,  and  UC  from  26.9  to  27.7.  Those  data  place
Mexico  within  the  range  of  Latin  America  and  the  regions
in  the  process  of  westernization  in  general,  although  with
marked  differences.  From  a  systematic  review  (1990--2016),
Ng  et  al.3 recently  reported  (2017)  a  regional  prevalence
(for  every  100,000  inhabitants)  for  IBD:  in  North  America,
a  range  of  96.3--318.5  for  CD  and  139.8--286.3  for  UC;  in




n  Africa,  19.02  for  CD  and  10.57  for  UC;  in  South  Asia,  1.2
or  CD  and  5.3--44.3  for  UC;  in  Latin  America,  0.9--41.4  for
D  and  4.7--44.3  for  UC.
Our  findings  described  a  bimodal  distribution  of  hos-
italizations  for  CD  in  young  adults  and  the  elderly.
ospitalizations  due  to  UC  also  exhibited  a  curve  with  two
eaks,  similar  to  our  findings  on  CD,  but  different  from  those
f  Sonnenberg.  Regarding  hospitalization  distribution  by  age
roup,  Sonnenberg25 analyzed  17  years  of  hospital  discharges
n  England  and  Scotland  and  found  a  double  peak  pattern  in
D  (25--29  years,  and  75--79  years)  and  one  basically  uni-
odal  in  UC,  with  the  peak  in  older  patients  (≥75  years).
evertheless,  close  to  50%  of  hospitalizations  occurred  in
atients  >50  years  of  age,  and  in  CD  the  two  peaks  were
ituated  in  the  age  groups  of  20--39  years  and  >60  years,
espectively.
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Table  6  Inflammatory  bowel  disease  in  Mexico  in  2015:  average  rate  of  treatment-refractory  cases.
Treatment  lines  Public  Private
Crohn’s  disease
%  of  first-line  treatment-refractory  cases  43.0%  41.3%
% of  second-line  treatment-refractory  cases  34.2%  30.2%
% of  anti-TNF  treatment-refractory  cases  41.9%  37.7%
Ulcerative colitis
% of  first-line  treatment-refractory  cases  24.9%  22.0%
% of  second-line  treatment-refractory  cases  32.5%  33.4%


















































































An  experience  in  Chile  was  recently  reported,  with
espect  to  hospitalizations  for  IBD,  using  the  same  methodol-
gy  as  in  our  study.  Those  authors  compared  the  admission
haracteristics  in  patients  hospitalized  for  IBD  (ICD-10-CM
50  and  K51)  between  two  non-consecutive  periods  of  2
ears  each,  selected  at  random:  2008  and  2009  versus  2013
nd  2014.  In  the  first  period,  the  rate  of  hospitalizations
ue  to  IBD  was  1.47/100,000  person-years.  In  the  second,
t  was  3.25/100,000  person-years.  That  finding  represents
 2.2-fold  increase  in  the  hospitalization  rate  (p  <  0.01)
nd  the  working-age  population  was  the  most  affected.26
n  our  study,  the  rate  of  hospitalization  for  IBD  corre-
ponded  to  1.55/100,000  person-years,  but  the  trend  shown
n  the  Chilean  study  is  similar  to  that  reported  by  Bosques-
adilla.8
A  systematic  review  was  conducted  on  that  same  topic
o  identify  population-based  studies  reporting  hospitaliza-
ion  rates  (or  crude  hospitalizations)  after  the  year  2000,
ith  at  least  5  years  of  data.  Log-linear  models  were  used
o  calculate  the  average  annual  percentage  change  (AAPC),
ith  associated  95%  confidence  intervals  (CIs).  Hospitaliza-
ions  for  IBD  in  North  America  and  Europe  were  divergent,
hat  is,  they  increased  in  some  countries  and  decreased  in
thers.  In  contrast,  the  results  showed  that  although  newly
ndustrialized  countries  outside  the  Western  world  have  the
owest  hospitalization  rates,  those  rates  are  rapidly  increas-
ng  in  South  America  (e.g.,  Mexico  [2000--2015]  AACP:
.67;  95%  CI:  2.8,  4.55),  the  Middle  East  (Bahrain),  and
sia  (China).  Those  rapidly  rising  hospitalization  rates  are
ontributing  to  an  increasing  burden  on  local  healthcare
ystems.27
In  2015,  we  documented  mortality  rates  of  0.56  and  3.7
or  CD  and  UC,  respectively.  They  represent  a  2.44-fold
ncrease  in  the  mortality  rate  of  CD  over  10--25  years,  and
 6.24-fold  increase  in  the  mortality  rate  of  UC  during  the
ame  period.  We  estimated  the  standardized  mortality  rate
ndirect  (SMRI)  for  2015,  resulting  in  1.26  for  CD  and  2.53  for
C,  both  in  the  total  population.  Regarding  CD,  incremental
isk  was  situated  mainly  in  the  age  group  <60  years  (partic-
larly  the  group  of  30--39  years  of  age  [22.77]),  whereas  for
C,  the  incremental  risk  was  distributed  similarly  in  virtually
ll  age  groups.  With  respect  to  IBD  mortality  in  Mexico,  our
esearch  data  showed  a  significant  increase,  when  compared
ith  the  information  reported  by  Sonnenberg.28 According
o  that  source,  in  the  period  of  1991--2004  in  Mexico,  the




iving  inhabitants)  and  for  UC  was  0.60.  For  that  same  indi-
ator,  Burisch  et  al.  reported  an  SMRI  for  CD  of  1.39  (95%
I,  1.30--1.49),  and  of  1.1  for  UC  (95%  CI,  0.9  - 1.2)  in
he  European  Union  (EU,  pooled  data  2013).29 That  mortal-
ty  data  supports  the  increase  in  the  burden  of  disease  in
exico.
Our  findings  are  similar  to  those  in  the  EU  regarding
D,  but  are  discordant  with  respect  to  UC,  in  which  the
urden  due  to  increased  risk  vs.  that  of  the  general  pop-
lation  is  comparatively  very  high  in  Mexico.  According  to
onnenberg,28 Mexico  is  in  a  range  similar  to  that  reported
or  CD  in  Hong  Kong  (0.58),  Taiwan  (0.45),  and  Japan  (0.37)
n  the  period  of  1991--2004.  In  terms  of  UC,  it  positions
exico  at  the  level  of  Argentina  (0.67)  over  the  same
eriod,  as  well.
With  respect  to  the  trend  of  treatment,  the  present  study
evealed  a  prescription  of  anti-TNF  therapy  in  CD  similar  to
r  slightly  higher  than  that  reported  in  previous  literature
p  to  2015.  Van  der  Valk  et  al.30 reported  the  following  use
f  anti-TNF  therapy  in  Denmark  (2011)  in  1315  patients  with
D:  infliximab  use  in  10.4%  and  adalimumab  in  12.3%,  com-
ared  with  the  22.7%  and  28.2%  in  our  study.  In  937  patients
ith  UC  they  found  infliximab  use  in  3%  and  adalimumab  in
%  (4%),  whereas  average  use  in  our  study  was  much  higher
t  19%.
Concerning  the  resistance  to  or  failure  of  anti-TNF  ther-
py,  our  results  showed  rates  of  37.7%  and  41.9%  for  CD  and
2.5%  and  43.7%  for  UC  (private  and  public  sectors,  respec-
ively),  in  line  with  the  international  literature  consulted
36--40%).20
The  total  direct  medical  costs  of  IBD  (2013)  have  been
eported  at  around  D  1871  (SD  D  4884),  with  the  cost  of  CD
D  2548  per  patient-year)  higher  than  that  of  UC  (D  1574).  In
he  pre-biologic  era,  hospitalization  due  to  CD  accounted  for
3%  of  the  total  direct  costs,  whereas  for  UC  it  was  45%.  With
he  use  of  anti-TNF  therapy,  medical  treatment  now  repre-
ents  64%  of  the  total  direct  medical  cost  of  CD,  and  31%  of
C,  with  a  per  capita  quarterly  cost  of  D  1626  for  CD  and
 595  for  UC.30 Thus,  it  is  important  to  emphasize  that  IBD
an  be  associated  with  significant  financial  costs,  due  to  both
he  hospitalization  rate  and  the  specific  treatment  involving
he  use  of  biologic  products.  In  addition,  premature  death
30nd  disability  are  associated  with  the  loss  of  productivity.
e  did  not  analyze  healthcare  costs  in  our  research.
Basically,  the  methodology  utilized  in  our  study
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healthcare  system  sources  (specific  databases)  and  it  should
be  mentioned  that  the  administrative  databases  of  the
healthcare  registries  (outpatient  cases,  hospital  cases,
hospital  discharges,  diagnostic  tests,  procedures,  etc.)
have  been  in  use  for  several  years,  in  the  Americas  and
in  Europe.31 Among  the  different  administrative  health
databases,  hospital  discharges  have  been  the  most  widely
used.31 Registries  strengthen,  validate,  or  even  attempt  to
replace  the  population-based  epidemiologic  records,  with
applications  including  monitoring  and  surveillance.31,32 As  a
very  recent  example  of  those  applications  in  Latin  Amer-
ica,  specifically  in  IBD,  an  analysis  of  hospitalizations  was
published  from  registers  using  ICD-10  codes  in  Chile.26 In
addition,  another  recent  report  used  the  same  methodol-
ogy  as  our  own  to  analyze  the  hospitalization  for  pneumonia
among  the  elderly  as  information  of  morbidity  and  increased
healthcare  utilization.33
Administrative  healthcare  databases  have  strengths  that
enable  them  to  serve  multiple  purposes,  such  as  those
mentioned  above.  They  are  also  relatively  inexpensive  and
easy  to  obtain  and  use,  when  compared  with  the  cost
and  time  invested  to  obtain  the  same  data  through  other
means,  such  as  surveys  or  clinical  record  abstraction.  Fur-
thermore,  they  are  considered  more  reliable  than  other
data  sources,  such  as  self-reported  patient  outcomes,  or
physician  round  tables,  that  in  general  represent  their  spe-
cific  experience  with  regard  to  disease  surveillance  and
resource  use.  Administrative  healthcare  databases  are  gen-
erally  available  for  several  years,  making  trend  analysis
possible,32 and  given  their  coverage  of  large  populations,
they  can  be  used  for  the  analysis  of  specific  facts  or  popu-
lation  subgroups.
The  thoroughness  of  employing  administrative  databases
using  ICD-coded  registries  as  a  method  vs.  a  clinical  one
is  accepted  in  several  international  studies,  with  a  70--90%
correlation.33 In  other  words,  with  the  method  used  in  the
present  study,  around  85%  of  the  data  is  accepted  by  the
international  community,  on  average,  as  fully  reliable.  It
has  also  been  specifically  stated  that  80--90%  of  records
coded  as  ICD-10  are  correct  in  terms  of  their  correlation
with  accepted  clinical  and  paraclinical  support.34 In  addi-
tion,  a  10--20%  overestimation  of  IBD  in  highly  industrialized
countries  has  been  found,  a  fact  not  seen  in  developing
countries.34
Despite  the  considerable  advantages  of  administrative
healthcare  databases,  there  are  also  weaknesses  that  may
limit  their  usefulness  for  certain  applications,  such  as  differ-
ences  in  the  methods  and  policies  of  collecting  information
among  health  systems  and  countries,  consequently  compro-
mising  database  comparability.  Said  differences  can  lead  to
varying  degrees  of  underreporting,  albeit  that  phenomenon
is  internationally  accepted  to  be  limited  to  between  10  and
20%.
Those  weaknesses  are  importantly  minimized  by  using
standardized  and  universally  accepted  classifications,  such
as  the  current  ICD-10  coding,  and  through  initiatives
in  some  parts  of  the  world  to  increase  and  improve
the  quality  of  the  data  available  in  the  database
registries.31
Finally,  it  is  very  clear  (and  totally  coincident  with  the
intention  of  the  authors  of  the  present  manuscript)  that  IBD,






egistered  directly,  diligently,  and  systematically,  in  accor-
ance  with  its  presumed  high  individual  and  social  costs
elated  to  health  and  quality  of  life,  health  resource  use,
nd  the  impact  on  health  systems,  consequently  reflecting
ts  burden  of  disease  for  Mexican  society  in  general.  Simply
tated,  specific  actions  must  be  taken  to  increase  the  quality
f  the  IBD  records  and  registration  processes.
In  many  cases,  including  the  present  study,  the  clinical
nd  therapeutic  information  is  not  sufficiently  detailed  or
obust,  forcing  the  use  of  other  alternative  methods  for
btaining  said  information.  That  information  in  our  study
as  derived  from  a Delphi  panel  of  physicians  and  must  be
onsidered  qualitative,  rather  than  quantitative  data.  The
xamination  of  clinical  information  and  its  correlation  with
he  types  of  treatment  presented  herein  is  only  an  overview
f  the  experience  of  a  group  of  Mexican  physicians  in  the
ublic  and  private  sectors.  As  an  additional  and  complemen-
ary  phase  of  the  present  study,  deeper  and  more  extensive
esearch  regarding  therapy  and  its  correlation  with  the  clin-
cal  status  of  the  patients  should  be  developed,  as  well  as
n  exercise  in  the  cost  component,  to  complete  the  analysis
f  the  burden  of  IBD.
It is  important  to  consider  that  our  data  refers  to  the
revalence  of  medical  attention.  That  is  to  say,  it  only  con-
iders  cases  captured  in  the  health  system  through  registries
rom  2015.
According  to  the  data  obtained  in  our  research  and  the
esults  shown  by  other  authors  of  studies  carried  out  on
ifferent  types  of  populations  and  geographic  areas,  it  is
lear  that  IBD  shows  an  increasing  trend  worldwide,  with
atin  America  as  one  of  the  regions  with  an  accelerated
xpansion  of  cases,  both  at  the  present  time  and  in  the
uture.23 Together  with  the  recognition  of  the  epidemio-
ogic  trend  of  IBD  in  the  Mexican  environment,  awareness
f  healthcare  resource  use  (medical  attention,  hospitaliza-
ion,  etc.)  related  to  patient  age  and  sex,  and  knowledge
f  the  specific  mortality,  are  extremely  important  for  esti-
ating  the  burden  of  disease,  in  addition  to  having  a
etter  understanding  of  the  problem.  Ideally,  in  our  envi-
onment,  we  must  strive  to  know  the  different  components
rom  which  we  can  build  complex  indicators  that  assess
he  burden  of  disease  in  an  integral  manner,  such  as  the
isability-adjusted  life  years  (DALYs)  (years  of  healthy  life
ost).
In  our  specific  case,  we  consider  that  the  analysis  of  the
ases  that  received  medical  attention  and  the  cases  hospi-
alized,  identified  through  ICD-10  coding  (ICD-10:  K50  and
51),  can  function  as  a  proxy  variable  of  disease  preva-
ence,  allowing  different  healthcare  resource  use  metrics  to
e  employed.  Most  importantly,  it  can  facilitate  the  analysis
f  trends  in  the  behavior  of  the  condition,  aiding  in  decision-
aking  regarding  the  approach  to  IBD  management,  in  the
exican  context.
We can  conclude  that  several  IBD  metrics  are  chang-
ng,  demonstrating  its  growth  trend  throughout  the  world,
articularly  in  developing  countries,  with  an  emphasis  on
n  upward  trend  in  Latin  America,  including  Mexico.  Said
onclusion  can  be  drawn,  despite  having  limited  informa-
ion  and  generally  indirect  measurements  of  the  behavior
f  the  cases,  with  discontinuity  in  the  timeline.  Those  insuf-
ciencies  underline  the  need  for  more  detailed  knowledge






































































etermining  indicators  of  incidence  and  prevalence,  by  cov-
ring  information  on  specific  mortality  and  health  resource
se  and  related  costs,  so  that  the  burden  of  disease  can  be
ully  determined  and  better  understood.  That  would  enable
ong-term  monitoring  of  IBD,  resulting  in  better  local  mana-
ement  of  the  disease,  as  well  as  in  systematic  comparisons
ith  the  rest  of  Latin  America  and  the  world,  in  general.
Therefore,  far  from  being  discouraged  by  the  lack  of  var-
ous  elements  of  analysis,  we  are  using  those  available  to
evelop  a  methodology  to  assess,  evaluate,  and  monitor
he  disease  in  the  future,  but  starting  now,  with  the  pos-
ibility  of  international  comparisons  and  discussions,  and
learly  with  the  aim  of  continuously  improving  the  measure-
ents.
At  present,  the  authors  maintain  that  the  method  uti-
ized,  and  the  information  reported  herein,  are  valuable  and
orthy  of  consideration,  given  the  almost  complete  absence
f  systematized  and  comparable  information  on  this  topic  in
exico.
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